Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T22:37:46.586Z.
Calculation as of: 2026-10-06T22:37:46.586Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 619c5482a9d59cec4bb20d2c4447c35828cdfaa1e6076b938dd954a9c5cde0ad
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Mineralys Therapeutics, Inc.
Market Cap
$1.94B
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.92B
EV/Sales Ratio
8.60x
TTM Avg
10.77x
3Y Avg
8.72x
5Y Avg
9.74x
Market Cap
$1.96B
EV/Sales Ratio
5.84x
TTM Avg
26.93x
3Y Avg
19.03x
5Y Avg
13.45x
Market Cap
$1.97B
EV/Sales Ratio
2.08x
TTM Avg
2.16x
3Y Avg
5.43x
5Y Avg
11.69x
Market Cap
$1.98B
EV/Sales Ratio
1.09x
TTM Avg
0.86x
3Y Avg
1.05x
5Y Avg
1.09x
Market Cap
$1.89B
EV/Sales Ratio
18.56x
TTM Avg
32.21x
3Y Avg
52.53x
5Y Avg
140.66x
Market Cap
$1.89B
EV/Sales Ratio
18.27x
TTM Avg
14.52x
3Y Avg
11.97x
5Y Avg
10.42x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | $1.94B | N/A | N/A | N/A | N/A |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.92B | 8.60x | 10.77x | 8.72x | 9.74x |
| AxoGen, Inc. (AXGN)vs › | $1.95B | 7.48x | 7.64x | 4.66x | 4.12x |
| Vir Biotechnology, Inc. (VIR)vs › | $1.96B | 5.84x | 26.93x | 19.03x | 13.45x |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.97B | 2.08x | 2.16x | 5.43x | 11.69x |
| Fortrea Holdings Inc. (FTRE)vs › | $1.98B | 1.09x | 0.86x | 1.05x | 1.09x |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | 18.56x | 32.21x | 52.53x | 140.66x |
| Zymeworks Inc. (ZYME)vs › | $1.89B | 53.23x | 22.33x | 13.89x | 12.70x |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 18.27x | 14.52x | 11.97x | 10.42x |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.87B | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
